Founding offer · lifetime membership for a single £24, exclusive to our first members · closes 20 June Claim your place →
Global Research Partnerships £24 Lifetime Log inCreate free account

Funded Projects › HORIZON

DAEDALUS · ADvAnced 4D biomAteriaLs for mucosa and sub-mUcosa treatment in patients affected by intestinal diSeases

HORIZONStatus: SIGNED1 June 202531 May 2029EU funding €7,760,778Call HORIZON-CL4-2024-RESILIENCE-01-TWO-STAGE

4D biomaterials enable new surgical treatments by autonomously acting in response to environmental stimuli, thus overcoming the limitations of standard medical strategies. DAEDALUS has the ambitious goal to develop two advanced 4D composite biomaterials designed to facilitate the re-epithelization of the colorectal mucosa and submucosa after their removal. Thus, DAEDALUS will provide an effective solution for addressing pathologies related to colorectal mucosa and submucosa, which are currently managed through proctocolectomy (removal of colon and rectum), a surgical procedure associated with drastic side effects. DAEDALUS biomaterials will combine synthetic and natural polymers (also derived from waste sources), with smart nano- and micro-carriers/particles. With the support of in silico tools, the biomaterials will be tailored to re-epithelize the mucosa and submucosa, adhere to each other and to the underlying muscle, and enable the release of oxygen, glucose, growth factors, and antibacterial and antifibrotic molecules. Moreover, the mucosal formulation will feature a shape morphing behavior triggered by a combination of magnetic field and light to mimic the colorectal mucosal crypts. To enable in situ printing of DAEDALUS biomaterials and provide the required stimuli, a multifunctional endoscope with a customized toolhead will be designed and validated ex vivo and in vivo. Throughout the project, the clinical translation of the DAEDALUS solutions will be continuously sought through: i) scaling up of the manufacturing routes by industrial partners, ii) feedback and acceptability from surgeons within the consortium, iii) social acceptance by patients and public. Moreover, the EU regulation framework will be identified to guarantee safe and effective solutions. Collectively, DAEDALUS will introduce a minimally invasive alternative to proctocolectomy and is expected to have a high impact on the quality of life of patients affected by colorectal pathologies.

Consortium · 14 organisations

coordinator

UNIVERSITA DI PISA

IT · €1,097,148

participant

UNIVERSITAETSKLINIKUM WUERZBURG - KLINIKUM DER BAYERISCHEN JULIUS-MAXIMILIANS-UNIVERSITAT

DE · €721,313

participant

UNIVERSITEIT GENT

BE · €1,138,522

participant

ADBIOINK BIYOSISTEM TEKNOLOJI ANONIM SIRKETI

TR · €414,422

participant

4TISSUE

BE · €375,200

participant

UNIVERSITA DEGLI STUDI DI TORINO

IT · €445,604

participant

LUXEMBOURG INSTITUTE OF SCIENCE AND TECHNOLOGY

LU · €441,932

participant

ERA ENDOSCOPY SRL

IT · €305,607

participant

ASOCIACION DE INVESTIGACION DE LA INDUSTRIA DEL JUGUETE CONEXAS Y AFINES

ES · €261,750

participant

BEWARRANT

BE · €367,583

participant

THIOMATRIX FORSCHUNGS UND BERATUNGS GMBH

AT · €620,568

participant

POLITECNICO DI TORINO

IT · €988,925

participant

CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRS

FR · €582,205

thirdParty

TINEXTA INNOVATION HUB S.P.A.

IT

Research fields

View the official record on CORDIS →

← Find collaborators and more funded projects

Source: CORDIS, Publications Office of the European Union. Global Research Partnerships surfaces open EU research data to help you find collaborators; we are not affiliated with the European Union.